The Acton, Mass.-based tubeless insulin pump manufacturer announced profits of $11.6 million or $0.17 per share on sales of $234 million for the three months ended September 30, 2020, for a bottom-line gain of 13.5% on sales growth of 21% compared with Q3 2019.
Insulet’s quarterly earnings of $0.18 surpassed the consensus estimate of $0.06 per share.
